Recent news highlights focus on Haemonetics' Q4 2026 earnings and revenue surpassing estimates, product enhancements with FDA clearances, and strategic acquisitions.

• Haemonetics reported Q4 2026 earnings and revenues surpassing estimates, with gross margin reductions noted [N1].
• The company held a Q4 earnings call highlighting operational and financial results [N2].
• The Q4 2026 earnings transcript provides detailed insights into company performance and strategy [N3].
• Haemonetics announced FDA clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology, enhancing plasma yield per donation [N4].
• The company completed the acquisition of Vivasure Medical Limited, expanding its product portfolio [N5].

Haemonetics benefits from a diversified portfolio addressing critical needs in plasma collection, blood component collection, and hospital patient care technologies. The Plasma and Hospital segments are positioned as growth drivers, supported by recent FDA clearances for advanced plasma collection technologies and vascular closure devices. The company's integrated software platforms enhance operational efficiency for customers. Strategic acquisitions, such as Vivasure Medical, expand product offerings. Strong customer relationships and global reach provide a foundation for sustained business activity. The company's investment in R&D and intellectual property portfolio support ongoing innovation and competitive differentiation [S1][N1].

Challenges include operating in the Blood Center segment, which faces more difficult market conditions and declining revenue contribution. Supply chain unpredictability for raw materials and components may increase costs or limit product availability. The company is exposed to regulatory risks, including the need for FDA clearances and compliance with evolving healthcare regulations. Competitive pressures in medical technology markets require continuous innovation and investment. Customer concentration risk exists, with a significant portion of revenue derived from a limited number of customers. Macroeconomic and geopolitical uncertainties could impact manufacturing costs and demand [S1].

Haemonetics' competitive advantages stem from its comprehensive product portfolio across plasma collection, blood center, and hospital technologies, supported by proprietary automated collection systems and integrated software solutions. The company has established long-term agreements with major U.S. plasma customers and has a history of FDA clearances for innovative product enhancements, such as the NexSys PCS with Persona PLUS technology. Its vascular closure devices have clinical trial validation and FDA approvals that support differentiated market positioning. The company's global sales network and customer collaborations further strengthen its market presence. Intellectual property protection through patents and trade secrets adds to its moat. However, the company faces supply chain risks and operates in competitive markets requiring continuous innovation [S1].

• Supply Chain Risks: Unpredictability in the supply of raw materials and components could increase costs or limit the company's ability to meet customer demand.
• Regulatory and Compliance Risks: The company depends on FDA clearances and regulatory approvals for its products; changes in regulations or failure to obtain approvals could adversely affect operations.
• Market and Competitive Risks: Competitive pressures in the medical technology industry require ongoing innovation and investment; failure to maintain technological leadership could impact market position.
• Customer Concentration: A significant portion of revenue is derived from a limited number of customers, which could impact financial performance if relationships change.
• Macroeconomic and Geopolitical Risks: Global economic conditions, inflation, tariffs, and geopolitical developments may affect manufacturing costs and supply chain stability.

• Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency through innovative solutions in hospital technologies, plasma collection, and blood center products [S1].
• The company operates in three principal segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices, disposables, and donor management software. Blood Center includes blood collection and processing devices and disposables for plasma, red cells, and platelets. Hospital includes Interventional Technologies (Vascular Closure, Sensor-Guided Technologies, Esophageal Protection) and Blood Management Technologies (Hemostasis Management, Cell Salvage, Transfusion Management) [S1].
• Plasma and Hospital segments are considered to have the greatest growth potential, while Blood Center operates in more challenging markets with a focus on targeted opportunities, especially in plasma and platelets [S1].
• The Plasma business offers automated plasma collection systems and software solutions to optimize yield, efficiency, quality, and donor experience at plasma collection centers. The NexSys PCS plasmapheresis collection system and related disposables are key products, with recent FDA clearances for Persona PLUS technology and Express Plus technology enhancing plasma yield and reducing procedure time [S1].
• The company has agreements with all U.S. plasma customers to adopt NexSys PCS in their global collection networks and has completed conversion to Express Plus and Persona technologies as of fiscal 2026 end [S1].
• Plasma segment represented approximately 39.3% of total revenue in fiscal 2026 [S1].
• The Blood Center segment provides automated blood component collection systems to optimize collections, improve donor safety, and control costs. The company divested its Whole Blood product line in fiscal 2025 to focus on higher margin and growth opportunities [S1].
• Blood Center segment represented 16.6% of total revenue in fiscal 2026 [S1].
• The Hospital segment includes Interventional Technologies and Blood Management Technologies, both with leading market positions aimed at improving patient care while reducing costs [S1].
• Interventional Technologies include Vascular Closure devices such as the VASCADE family, which reduce access site complications and improve hospital workflow. The VASCADE MVP XL received FDA approval expansion for larger sheath sizes used in advanced procedures [S1].
• The PerQseal Elite large bore closure system targets large bore femoral access closure and has CE Mark in Europe with a PMA application submitted to the FDA [S1].
• Sensor-Guided Technologies include OptoWire pressure guidewire and SavvyWire 3-in-1 guidewire for TAVR procedures [S1].
• Esophageal Protection products include the ensoETM system, which provides proactive cooling during radiofrequency cardiac ablation to reduce esophageal injury risk [S1].
• Blood Management Technologies include Hemostasis Management, Cell Salvage, and Transfusion Management products designed to improve clinical decision-making, patient safety, and operational efficiency [S1].
• Haemonetics markets and sells products in approximately 90 countries through direct sales forces and independent distributors, with the top ten customers accounting for about 44% of net revenues in fiscal 2026 [S1].
• The company invests in research and development focused on product innovation, regulatory compliance, and customer collaboration, primarily supporting Plasma and Hospital portfolios [S1].
• Manufacturing is conducted in controlled clean room environments with primary consumable manufacturing in North America and Malaysia, and capital equipment manufacturing in Malaysia, Australia, and the U.S. [S1].
• Haemonetics has experienced supply chain unpredictability for certain raw materials and components, which could increase costs or limit product availability [S1].
• The company holds numerous patents and trademarks in the U.S. and selected foreign countries to protect its intellectual property and relies on technical expertise and trade secrets [S1].
• Financial snapshot as of March 28, 2026: cash and equivalents of $245.44 million, current assets of $834.88 million, current liabilities of $282.60 million, current ratio of 2.95, and cash ratio of 0.87. Net income for fiscal 2026 was $97.31 million with basic EPS of $2.06 and diluted EPS of $2.05 [S1].
• Recent news highlights include Q4 2026 earnings and revenue surpassing estimates, gross margin reductions, and FDA clearances for product enhancements. The company also completed the acquisition of Vivasure Medical Limited in early 2026 [N1][N2][N3][N4][N5].